DYN
Dyne Therapeutics Inc.
$21.18
+$1.06(+5.27%)
63
Overall
60
Value
66
Tech
--
Quality
Market Cap
$1.87B
Volume
1.91M
52W Range
$6.36 - $31.32
Target Price
$35.76
Company Overview
| Mkt Cap | $1.87B | Price | $21.18 |
| Volume | 1.91M | Change | +5.27% |
| P/E Ratio | -5.9 | Open | $19.91 |
| Revenue | -- | Prev Close | $20.12 |
| Net Income | $-317.4M | 52W Range | $6.36 - $31.32 |
| Div Yield | N/A | Target | $35.76 |
| Overall | 63 | Value | 60 |
| Quality | -- | Technical | 66 |
No chart data available
About Dyne Therapeutics Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Latest News
Dynagreen’s Shareholders Approve Key Resolutions at 2025 EGM
TipRanks HongKong Auto-Generated Newsdesk•4 days ago
Palladyne AI Corp Unveils Defense-Focused Transformation
TipRanks Auto-Generated Newsdesk•5 days ago
Dynatronics Delays Form 10-Q Filing
TipRanks Auto-Generated Newsdesk•6 days ago
Dyne Therapeutics (DYN) Gets a Hold from Oppenheimer
TipRanks Auto-Generated Intelligence Newsdesk•11 days ago
Grid Dynamics Faces Investor Scrutiny as Executives Plan Major Stock Sales
TipRanks Auto-Generated Newsdesk•22 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DYN | $21.18 | +5.3% | 1.91M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |